new medicines

Boehringer to Expand Greek Production Site for New Medicines

German drugmaker Boehringer Ingelheim is investing €120 million in an upgrade and expansion of its facility in Koropi, Greece, that will increase the company's capacity to produce existing and new medicines. Main disease areas, Boehringer said, include cardio-renal-metabolic (CRM) diseases, mental health, and pulmonary fibrosis.

News

US FDA New Drug Approvals Hit 16-Year High in 2012

Top-Feature

Bio-Rad Laboratories

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

Concept Heidelberg

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance

Brenntag SE

Brenntag Downsizes Management Board, Retains Both Divisions

CHEManager International c/o Wiley-VCH GmbH

20 Years of CHEManager International

Nova-Institut GmbH

Advanced Recycling Conference 2025: New Paths to the Circular Economy

Hamilton Bonaduz AG

Optimize Your Process with Smart Oxygen Sensors for Inertization and Blanketing Applications

CHEManager International c/o Wiley-VCH GmbH

API Manufacturing

Interview

Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Boehringer Ingelheim